Establishing 17-Hydroxyprogesterone Cutoff Values for Congenital Adrenal Hyperplasia in Preterm, Low Birth Weight, and Sick Newborns

Abstract

Background Newborn screening for congenital adrenal hyperplasia (CAH) has benefits with a high adoption rate worldwide. It also has problems of high false positives, which can cause stress to the patient’s family with economic losses and unnecessary visits of newborns to hospitals. Therefore, we investigated the influence of birth weight (BW), gestational age (GA), and GA with sampling time on 17-hydroxyprogesterone (17-OHP) concentration and attempted to establish the 17-OHP cutoff values in preterm, low birth weight (LBW), and sick newborns.

Methods Newborns (n=1,071) born between October 2020 and January 2022 were screened for CAH. Samples from neonates were collected on filter paper with the heel prick method. 17-OHP concentration was measured by time-resolved immunofluorescence with an AutoDELFIA Neonatal 17-hydroxyprogesteron kit and grouped in relation to BW, GA, and GA with sampling time.

Results The median age of newborns at neonatal sample collection was 6 days. 17-OHP concentration showed a statistically significant negative correlation with BW (r=−0.488, p<0.001) and GA (r=−0.560, p<0.001). Full-term and preterm subgroups had a similar decreasing tendency of 17-OHP concentration with increasing sampling time. Application of newly establishing cutoff criteria significantly reduced recall rates to 1.16%, 0.9%, and 1.75% according to each criterion of BW, GA, and GA with sampling time, respectively.

Conclusions This study presents new 17-OHP cutoff values for preterm, LBW, and sick newborns. These data in our laboratory can be used as a reference by other laboratories for establishing new cutoff criteria to help lower the high recall rate and reduce unnecessary follow-up tests.

Key words

17-hydroxyprogesterone - newborn - congenital adrenal hyperplasia - preterm

Publication History

Received: 15 May 2022
Received: 28 December 2022

Accepted: 25 January 2023

Article published online:
28 February 2023

• References

• 1 Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med 2003; 349: 776-788
• 2 White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000; 21: 245-291
• 3 Tsuji-Hosokawa A, Kashimada K. Thirty-year lessons from the newborn screening for congenital adrenal hyperplasia (CAH) in Japan. Int J Neonatal Screen 2021; 7: 36
• 4 Choi TYKJ, Lee DH, Song WH. Cutoff Value of 17-hydroxyprogesterone screening test for congenital adrenal hyperplasia according to birth weight. J Lab Med Qual Assur 2009; 31: 269-274
• 5 Hayashi GY, Carvalho DF, de Miranda MC. et al. Neonatal 17-hydroxyprogesterone levels adjusted according to age at sample collection and birthweight improve the efficacy of congenital adrenal hyperplasia newborn screening. Clin Endocrinol 2017; 86: 480-487
• 6 Jiang X, Tang F, Feng Y. et al. The adjustment of 17-hydroxyprogesterone cut-off values for congenital adrenal hyperplasia neonatal screening by GSP according to gestational age and age at sampling. J Pediatr Endocrinol Metab 2019; 32: 1253-1258
• 7 Fingerhut R. False positive rate in newborn screening for congenital adrenal hyperplasia (CAH)-ether extraction reveals two distinct reasons for elevated 17alpha-hydroxyprogesterone (17-OHP) values. Steroids 2009; 74: 662-665
• 8 Németh S, Riedl S, Kriegshäuser G. et al. Reverse-hybridization assay for rapid detection of common CYP21A2 mutations in dried blood spots from newborns with elevated 17-OH progesterone. Clinica Chim Acta 2012; 414: 211-214
• 9 Schwarz E, Liu A, Randall H. et al. Use of steroid profiling by UPLC-MS/MS as a second tier test in newborn screening for congenital adrenal hyperplasia: the Utah experience. Pediatr Res 2009; 66: 230-235
• 10 Held PK, Bird IM, Heather NL. Newborn screening for congenital adrenal hyperplasia: Review of factors affecting screening accuracy. Int J Neonatal Screen 2020; 6: 67
• 11 Gatelais F, Berthelot J, Beringue F. et al. Effect of single and multiple courses of prenatal corticosteroids on 17-hydroxyprogesterone levels: Implication for neonatal screening of congenital adrenal hyperplasia. Pediatr Res 2004; 56: 701-705
• 12 Rohrer TR, Gassmann KF, Pavel ME. et al. Pitfall of newborn screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Biol Neonate 2003; 83: 65-68
• 13 White PC. Neonatal screening for congenital adrenal hyperplasia. Nat Rev Endocrinol 2009; 5: 490-498
• 14 CLSI Newborn Screening by Tandem Mass Spectrometry. In: Wayne, PA ed, CLSI guideline NBS04. 2nd edition. Clinical and Laboratory Standards Institute; 2017
• 15 Votava F, Török D, Kovács J. et al. Estimation of the false-negative rate in newborn screening for congenital adrenal hyperplasia. Eur J Endocrinol 2005; 152: 869-874
• 16 Allen DB, Hoffman GL, Fitzpatrick P. et al. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels. J Pediatr 1997; 130: 128-133
• 17 van der Kamp HJ, Oudshoorn CG, Elvers BH. et al. Cutoff levels of 17-alpha-hydroxyprogesterone in neonatal screening for congenital adrenal hyperplasia should be based on gestational age rather than on birth weight. J Clin Endocrinol Metab 2005; 90: 3904-3907
• 18 Van der Kamp HJ, Noordam K, Elvers B. et al. Newborn screening for congenital adrenal hyperplasia in the Netherlands. Pediatrics 2001; 108: 1320-1324
• 19 Olgemöller B, Roscher AA, Liebl B. et al. Screening for congenital adrenal hyperplasia: Adjustment of 17-hydroxyprogesterone cut-off values to both age and birth weight markedly improves the predictive value. J Clin Endocrinol Metab 2003; 88: 5790-5794
• 20 Ohkubo S, Shimozawa K, Matsumoto M. et al. Analysis of blood spot 17 alpha-hydroxyprogesterone concentration in premature infants--proposal for cut-off limits in screening for congenital adrenal hyperplasia. Acta Paediatr Jpn: Overseas edition 1992; 34: 126-133
• 21 Figerhut R. False positive rate in newborn screening for congenital adrenal hyperplasia (CAH)-ether extraction reveals two distinct reasons for elevated 17alpha-hydroxyprogesterone (17-OHP) values. Steroids 2009; 71: 662-665
• 22 Seo JY, Park HD, Kim JW. et al. Steroid profiling for congenital adrenal hyperplasia by tandem mass spectrometry as a second-tier test reduces follow-up burdens in a tertiary care hospital: A retrospective and prospective evaluation. J Perinat Med 2014; 42: 121-127